Lakefront Biotherapeutic...【LKFT】銘柄情報

Lakefront Biotherapeutics NV (LKFT) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

28.02

( -0.32% )

買値

25.00

売値

42.14

出来高

138,613

27.88 日の範囲 28.42

26.42 52 週間の範囲 28.69

時価総額

1.846B

前日終値

28.11

始値

28.11

時刻

27.55

最終取引時間

財務取引量

US$ 3,902,167

VWAP

28.1515

平均取引量 (3 か月)

US$ 76,706

発行済株式数

65,897,071

配当利回り

PER

3.26

1 株当たり利益 (EPS)

7.42

歳入

1.04B

純利益

488.78M

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG51... Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. 詳細を表示

セクター

業界

ウェブサイト

lakefrontbio.com

本社

Mechelen, Belgium

設立

1999

Lakefront Biotherapeutics NV is listed in the sector of the ナスダック市場 with ticker LKFT. The last closing price for Lakefront Biotherapeutic... was US$28.11. Over the last year, Lakefront Biotherapeutic... shares have traded in a share price range of US$ 26.42 to US$ 28.69.

Lakefront Biotherapeutic... currently has 65,897,071 shares in issue. The market capitalisation of Lakefront Biotherapeutic... is US$1.85 billion. Lakefront Biotherapeutic... has a price to earnings ratio (PE ratio) of 3.26.

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T...

Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; May 26, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.23	-0.814159292035	28.25	28.69	26.92	237894	27.6125128	DR
4	0.02	0.0714285714286	28	28.69	26.42	184718	27.53281163	DR
12	0.02	0.0714285714286	28	28.69	26.42	184718	27.53281163	DR
26	0.02	0.0714285714286	28	28.69	26.42	184718	27.53281163	DR
52	0.02	0.0714285714286	28	28.69	26.42	184718	27.53281163	DR
156	0.02	0.0714285714286	28	28.69	26.42	184718	27.53281163	DR
260	0.02	0.0714285714286	28	28.69	26.42	184718	27.53281163	DR